Cover image of the article: Complete Genotype and Clinical Phenotype of Hemophilia B:  A Study on Iranian Patients

Image Credit:J Cell Mol Anesth

Complete Genotype and Clinical Phenotype of Hemophilia B: A Study on Iranian Patients

Authors

marzieh shakouri1,*, Maryam Sadat Hosseini2, Akbar Dorgalaleh1, Minoo ShahidiMinoo Shahidi ORCID1, Farhad Zaker3
1Department of Hematology and Blood Banking, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran
2Department of Hematology and Blood Banking, School of Allied Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
3Department of Hematology and Blood Banking, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran; Cellular and Molecular Research Center, Iran University of Medical Sciences, Tehran, Iran
*Corresponding Author: Department of Hematology and Blood Banking, School of Allied Medicine, Iran University of Medical Sciences, Tehran, Iran Email: shakouri.ma@gmail.com

Journal of Cellular & Molecular Anesthesia:Vol. 6, issue 1; e150285
Published online:Jan 14, 2021
Article type:Original Articles
How to Cite:shakouri M, Hosseini MS, Dorgalaleh A, Shahidi M, Zaker F. Complete Genotype and Clinical Phenotype of Hemophilia B: A Study on Iranian Patients. J Cell Mol Anesth. 2021;6(1):e150285. doi: https://doi.org/10.22037/jcma.v6i1.33722

Abstract

Background: Hemophilia B which refers to the deficiency or functional defect of factor IX (FIX) is typically an X-linked bleeding condition that arises from heterogeneous mutations of the FIX gene (F9). The number of hemophilia cases in Iran is considerable and currently, about 1118 Iranian patients are suffering from hemophilia B, although a small number of them underwent genetic investigations. Here we assessed molecular defects and also laboratory and clinical findings of 10 Iranian cases with hemophilia B. Materials and Methods: A total of 10 cases with hemophilia B were enrolled in the study. Patients were clinically examined by a hematologist and their previous medical documents were surveyed carefully. Routine coagulation tests and FIX activity and antigen assays were performed for the studied patients. Genotyping of F9 for identifying genetic mutations was conducted by the Sanger sequencing method following PCR amplification of the promoter region and all the eight exons of the F9 gene. Results: The mean age of patients was 4 years (9 months to 16 years) and consanguinity was reported in 80% of cases. Patients were commonly manifested by hematoma (90%), epistaxis (80%), and hemarthrosis (70%) and the severity of the disorder was severe (70%) or moderate (30%). In nine out of 10 patients a genetic defect in F9 gene we detected including three missense (c.304T>C, c.1007T>A, c.191G>A) and three nonsense mutations (c.892C>T, c.880C>T, c.1113C>A). Based on the FIX variant database (http://www.factorix.org), five mutations have been reported previously, but mutation c.1007T>A (p.Ile336Asn) seems to be a novel mutation. Conclusion: Our results indicated the heterogeneous molecular defects of hemophilia B in Iran, as recorded in the FIX mutation database. Moreover, no specific genotype-phenotype association was observed in studied subjects.

Highlights

References

  • 1.
    References are in the PDF file of the article.

Copyright

© 2021, Author(s). This open-access article is available under the Creative Commons Attribution 4.0 (CC BY 4.0) International License (https://creativecommons.org/licenses/by/4.0/), which allows for unrestricted use, distribution, and reproduction in any medium, provided that the original work is properly cited.

Similar Articles

10
Mar
2014
Unusual Prevalence of c559T > C Mutation in Patients with Factor XIII deficiency in Southeast of Iran

Unusual Prevalence of c559T > C Mutation in Patients with Factor XIII deficiency in Southeast of Iran

Ebrahim Miri-Moghaddam,
Yasaman Garmie,
Majid Naderi

Miri-Moghaddam E, Garmie Y, Naderi M. Unusual Prevalence of c559T > C Mutation in Patients with Factor XIII deficiency in Southeast of Iran. Gene Cell Tissue. 2014;1(1):e18314. doi: https://doi.org/10.17795/gct-18314

19
Jul
2011
Prevalence of factor VIII inhibitor in patients with hemophilia A in Sanandaj

Prevalence of factor VIII inhibitor in patients with hemophilia A in Sanandaj

Farzad Company,
Nazila Rezaei,
Mariam Aliasgharpoor

Company F, Rezaei N, Aliasgharpoor M. Prevalence of factor VIII inhibitor in patients with hemophilia A in Sanandaj. J Kermanshah Univ Med Sci. 2011;15(2):e79379. doi:

30
Sep
2008
Survey of the relationship between of thrombophilic factors and the rate and severity of bleeding in patients with severe hemophilia A

Survey of the relationship between of thrombophilic factors and the rate and severity of bleeding in patients with severe hemophilia A

Mohammad Faranosh,
Navid Danayie,
raheb Ghorbani,
Mahbobeh Rahamani,
Mohammad Jazebi,
Tahere Shashani
,et al.

Faranosh M, Danayie N, Ghorbani R, Rahamani M, Jazebi M, et al. Survey of the relationship between of thrombophilic factors and the rate and severity of bleeding in patients with severe hemophilia A. koomesh. 2024;9(4):e152211. doi:

29
Oct
2023
Evaluation of Cardiovascular Status in Hemophilia Patients in Dezful: Echocardiography, Electrocardiography, and Cardiac Risk Factors

Evaluation of Cardiovascular Status in Hemophilia Patients in Dezful: Echocardiography, Electrocardiography, and Cardiac Risk Factors

Hakimeh Saadatifar,
Rezvan Behrouzi,
Aziz Ghorban Shiravizadeh,
Neda Shakerian,
Samira Saadatifar

Saadatifar H, Behrouzi R, Shiravizadeh AG, Shakerian N, Saadatifar S. Evaluation of Cardiovascular Status in Hemophilia Patients in Dezful: Echocardiography, Electrocardiography, and Cardiac Risk Factors. J Adv Immunopharmacol. 2023;3(2):e139250. doi: https://doi.org/10.5812/tms-139250

1
Jan
2017
Genetic Risk Factors for Inhibitor Development in Patients with Hemophilia and Rare Bleeding Disorders

Genetic Risk Factors for Inhibitor Development in Patients with Hemophilia and Rare Bleeding Disorders

Taregh Bamedi,
Ghazaleh Dadashizadeh,
Afsaneh Sarabandi,
Shadi Tabibian,
Mahmood Shams,
Akbar Dorgalaleh

Bamedi T, Dadashizadeh G, Sarabandi A, Tabibian S, Shams M, et al. Genetic Risk Factors for Inhibitor Development in Patients with Hemophilia and Rare Bleeding Disorders. J Cell Mol Anesth. 2017;2(1):e149529. doi: https://doi.org/10.22037/jcma.v2i1.14481

More by these authors

marzieh shakouriPubMedScholar
Maryam Sadat HosseiniPubMedScholar
Akbar DorgalalehPubMedScholar
Minoo ShahidiPubMedScholar
Farhad ZakerPubMedScholar
Share
Cited by
Metrics
Indexed in